Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines - PubMed (original) (raw)
Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines
Mark E Law et al. Cancer Genet Cytogenet. 2005.
Abstract
Deletions of chromosome 1p and 19q arms are frequent genetic abnormalities in primary human gliomas and are especially common in oligodendrogliomas. However, the chromosome 1p and 19q status of many glioma cell lines has not been established. Using homozygosity mapping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization to arrayed BAC (CGHa), we screened 17 glioma cell lines for chromosome 1 and 19 deletions. Sequence tagged site polymorphisms were used to evaluate the cell lines for regions of chromosome 1p and 19q homozygosity. Cell lines A172, U251, TP265, U118, SW1088, U87, SW1783, and D32 contained significant regions of 19q homozygosity. In addition, A172, U87, TP483, D37, U118, MO67, and TP265 contained significant regions of 1p homozygosity. FISH probes localized to 1p36.32 and 19q13.33 as well as CGHa were used to determine which cell lines had deletions of 1p and/or 19q. Cell lines A172, U87, TP483, TP265, H4, U251, and D37 were deleted for portions of 1p. CGHa and homozygosity mapping of these cell lines define a 700-kilobase (Kb) common deletion region that is encompassed by a larger deletion region previously mapped in sporadic gliomas. This common deletion region is localized at 1p36.31 and includes CHD5, a putative tumor suppressor gene. Cell line A172 was observed to have a deletion between 19q13.33 and 19q13.41, while U87 was observed to have a smaller deletion of 19q13.33. Cell lines A172 and U87 contain 1p and 19q deletions similar to those found in sporadic gliomas and will be useful cellular reagents for evaluating the function of putative 1p and 19q glioma tumor suppressor genes.
Similar articles
- Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype.
Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB. Smith JS, et al. Oncogene. 1999 Jul 15;18(28):4144-52. doi: 10.1038/sj.onc.1202759. Oncogene. 1999. PMID: 10435596 - Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
Gadji M, Fortin D, Tsanaclis AM, Drouin R. Gadji M, et al. Cancer Genet Cytogenet. 2009 Oct;194(1):12-22. doi: 10.1016/j.cancergencyto.2009.05.004. Cancer Genet Cytogenet. 2009. PMID: 19737649 - Molecular pathogenesis of malignant gliomas.
Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD. Rasheed BK, et al. Curr Opin Oncol. 1999 May;11(3):162-7. doi: 10.1097/00001622-199905000-00004. Curr Opin Oncol. 1999. PMID: 10328589 Review. - Analysis of genomic imprinting at 1p35-36 in neuroblastoma.
Hogarty MD, Maris JM, White PS, Guo C, Brodeur GM. Hogarty MD, et al. Med Pediatr Oncol. 2001 Jan;36(1):52-5. doi: 10.1002/1096-911X(20010101)36:1<52::AID-MPO1014>3.0.CO;2-8. Med Pediatr Oncol. 2001. PMID: 11464906 Review.
Cited by
- Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma.
Peixoto J, Príncipe C, Pestana A, Osório H, Pinto MT, Prazeres H, Soares P, Lima RT. Peixoto J, et al. Int J Mol Sci. 2023 Jul 10;24(14):11285. doi: 10.3390/ijms241411285. Int J Mol Sci. 2023. PMID: 37511044 Free PMC article. - Comprehensive analysis of epigenetics regulation, prognostic and the correlation with immune infiltrates of GPX7 in adult gliomas.
Ferreira WAS, Vitiello GAF, da Silva Medina T, de Oliveira EHC. Ferreira WAS, et al. Sci Rep. 2022 Apr 19;12(1):6442. doi: 10.1038/s41598-022-10114-1. Sci Rep. 2022. PMID: 35440701 Free PMC article. - Coordinated Expression of Ras Suppressor 1 (RSU-1) and Growth Differentiation Factor 15 (GDF15) Affects Glioma Cell Invasion.
Louca M, Gkretsi V, Stylianopoulos T. Louca M, et al. Cancers (Basel). 2019 Aug 13;11(8):1159. doi: 10.3390/cancers11081159. Cancers (Basel). 2019. PMID: 31412547 Free PMC article. - Synergistic Action of Gefitinib and GSK41364A Simultaneously Loaded in Ratiometrically-Engineered Polymeric Nanoparticles for Glioblastoma Multiforme.
Velpurisiva P, Rai P. Velpurisiva P, et al. J Clin Med. 2019 Mar 15;8(3):367. doi: 10.3390/jcm8030367. J Clin Med. 2019. PMID: 30875975 Free PMC article. - Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
Han S, Meng L, Jiang Y, Cheng W, Tie X, Xia J, Wu A. Han S, et al. Br J Cancer. 2017 May 9;116(10):1302-1311. doi: 10.1038/bjc.2017.89. Epub 2017 Mar 30. Br J Cancer. 2017. PMID: 28359080 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials